Vascular calcification in ESRD: Another cloud appears in the perfect storm—but highlights a silver lining?  by Towler, Dwight A.
Kidney International, Vol. 66 (2004), pp. 2467–2468
EDITORIAL
Vascular calcification in ESRD: Another cloud appears in the
perfect storm—but highlights a silver lining?
The horrendous cardiovascular consequences of end-
stage renal disease (ESRD) are multifactorial; metabolic,
hypertensive, inflammatory, and electrolyte abnormali-
ties that drive macrovascular disease processes result in
the 20% annual mortality in our patients afflicted with
ESRD [1]. Severe vascular calcification is highly charac-
teristic of ESRD, a process that alters vascular compli-
ance and inhibits physiologic regulation of blood flow
and coagulation. At least four histoanatomic variants
of macrovascular calcification—intimal, medial, valvu-
lar, and vascular tissue calciphylaxis—have emerged [2].
Once thought benign, the deleterious consequences of
vascular calcification have become clear [3]. In the setting
of diabetes, medial calcification portends increased car-
diovascular mortality and risk of lower extremity ampu-
tation [4]. Aortic valve calcium content is the single best
predictor of clinical progression in extant asymptomatic
aortic stenosis [5]. In patients with ESRD, London
et al [6] have convincingly demonstrated that both medial
and intimal calcification portend mortality risk. Molec-
ular and histologic features of vascular osteogenesis
are evident in the first three variants listed above [2].
Recapitulating features of bone marrow stromal cell
physiology, vascular myofibroblasts contribute to car-
diovascular calcification; along with dystrophic calcium
deposition in dying cells and lipoprotein deposits, ac-
tive endochondral and intramembranous ossification
processes contribute to vascular calcium load. Mural
myofibroblasts and Sca1+ progenitors—arising from me-
dial and adventitial venues—are recruited in response
to oxidized lipids, inflammation, and mechanical injury
[2]. Paracrine vascular signals provided by bone morpho-
genetic protein-2, Wnts, parathyroid hormone–related
polypeptide, osteopontin, osteoprotegerin, and fetuin
complexes control calcium deposition, and are entrained
to endocrine, metabolic, inflammatory, and mechanical
cues [2].
In ESRD, a “perfect storm” of vascular calcification
arises, with hyperglycemia, hyperphosphatemia, hyperc-
holesterolemia, hypertension, parathyroid hormone re-
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sistance, and iatrogenic calcitriol excess contributing to
severe calcific vasculopathy [7]. In this issue of Kid-
ney International, Giachelli et al [8] identify yet another
metabolic parameter—serum calcium concentration—
that now must be independently considered in the
pathobiology and clinical management of vascular cal-
cification. At first glance, this may seem trivial, and, of
course, clinical guidelines already address this param-
eter. However, in a series of carefully performed ex-
periments, calcium is shown to promote cell-mediated
matrix calcification at any given phosphate concen-
tration; they demonstrate that elevated extracellular
calcium ion promotes the active, cell-mediated calcifica-
tion processes of vascular smooth muscle cells [8]. This
may occur in part via up-regulation of the type III Na/Pi
cotransporter (also known as Pit-1, Glvr-1, SCL20A1);
indeed, inhibition of cellular phosphate uptake with fos-
carnet inhibits calcium-induced VSMC calcification [8].
The Giachelli lab has previously shown that inorganic
phosphate (Pi) signaling via Pit-1 enhances expression
of Runx2/Cbfa1 [9], a chondro-osteogenic transcription
factor that participates in neovascularization, matrix syn-
thesis, and mineralization in bone. Of note, Runx2/Cbfa1
appears to be a general vascular “stress-responsive” gene,
inducible by mechanical injury [10] and uremia [11].
Whether these latter stressors also signal via Pit-1 to up-
regulate vascular Runx2/Cbfa1 is as yet unknown. Never-
theless, the observation that hypercalcemia up-regulates
Pit-1—the phosphate transporter that conveys procal-
cific osteogenic cellular responses to hyperphosphatemia
[12]—highlights the importance of this arterial vascular
smooth muscle cell signaling cascade to uremic vascular
disease. In the future, it should be possible, using either
genetically lesioned or pharmacologically manipulated
mice, to assess whether strategies that alter Pit-1 activ-
ities regulate vascular calcification responses in vivo as
observed in vitro. If so, pharmacologic manipulation of
vascular phosphate transporters, coupled with assiduous
metabolic control [13] and endocrine strategies that nor-
malize vascular and skeletal calcium flux [14, 15], may
help our patients to better weather the vasculopathy of
ESRD.
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